Hormonal
Pericardial fat volume is independently associated with coronary artery calcification (CAC) even after adjusting for visceral abdominal fat (VAT), BMI, waist circumference, and metabolic risk factors, suggesting a local toxic effect on the vasculature.
If you have metabolic risk factors (like high blood pressure or glucose) but a normal BMI, standard weight checks might miss hidden heart risks. Pericardial fat, which surrounds the heart, is a specific predictor of coronary artery calcification. While not everyone needs a CT scan, understanding that 'normal weight' doesn't guarantee zero vascular risk is key. If you are undergoing cardiac imaging for other reasons, ask if pericardial fat volume was assessed, as it provides independent risk data beyond just waist size.
Pericardial fat, but not intrathoracic fat, was associated with coronary artery calcification after multivariable and VAT adjustment (odds ratio 1.21, 95% confidence interval 1.005 to 1.46, P<0.04)... Conclusions—Pericardial fat is correlated with multiple measures of adiposity and cardiovascular disease risk factors, but VAT is a stronger correlate of most metabolic risk factors. However, intrathoracic and pericardial fat are associated with vascular calcification, which suggests that these fat depots may exert local toxic effects on the vasculature.
Why this rating
Large community-based sample (n=1155), rigorous CT volumetric measurement, and extensive multivariable adjustment, though cross-sectional design limits causal inference.
Source
Pericardial Fat, Visceral Abdominal Fat, Cardiovascular Disease Risk Factors, and Vascular Calcification in a Community-Based Sample
Guido Aranha Rosito et al. · Circulation · 2008
DOI 10.1161/circulationaha.107.743062
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →